The effect of lowering blood glucose regarding SGLT2 inhibitor in type 1 diabetes mellitus

The effect of lowering blood glucose regarding SGLT2 inhibitor in type 1 diabetes mellitus - The effect of SGLT2 inhibitor in type 1 diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000036098

Enrollment

Registered

2019-03-06

Start date

2019-03-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 diabetes mellitus

Interventions

Administrating Ipragliflozin 50 mg/day on basal-bolus insulin for 12 weeks Administrating Voglibose 0.9 mg/day on basal-bolus insulin for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 1 diabetic patients who treat only basal-bolus therapy

Exclusion criteria

Exclusion criteria: 1.Patients who treat with CSII. 2.Patients who have history of diabetic coma, severe diabetic ketosis or hyperglycemic hyperosmolar symdrome. 3.1. Patients with severe infection, severe injury or perioperative state. 4.1. Patients with severe diabetic complications such as neuropathy, retinopathy and nephropathy. 5.BMI of patients under 17.5 kg/m2. 6.eGFR of patients less than 45 mL/min/1.73m2. 7.Patients with history of ileus. 8.Patients with vulvitis. 9.Pregnant 10.Patients whom researchers rule out as inappropriate subjects.

Design outcomes

Primary

Measure	Time frame
HbA1c, Total daily dose of insulin, BMI	—

Secondary

Measure	Time frame
average blood glucose, standard deviation, mean amplitude of glycemic excursion	—

Countries

Japan

Contacts

Public ContactRyo Kumagai Ryo Kumagai

Tsukuba University Hospital Mito Clinical Education and Training Center Mito Kyodo General Hospital Endocrinology and Metabolism

kumaryo1818@gmail.com029-231-2371

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026